We confirmed potent inhibition of several off-targets and were keen on reducing the inhibition of FRAP1(mTOR), PIK3CA, and CDK7, as these kinases drive proliferation in breast cancer (Liu et al., 2009; Wang et al., 2015; Yu et al., 2001), which would complicate the interpretation of MELK-dependent pharmacology if inhibited. This evidence concerns the gene CDK7 and breast carcinoma.